> Disorders > Congenital Abnormality > Patent Ductus Arteriosus

Patent Ductus Arteriosus

Most cited protocols related to «Patent Ductus Arteriosus»

Infants born alive at NRN centers in 2003–2007 with GAs of 22 0/7 to 28 6/7 weeks and BWs of 401 to 1500 g were studied, including those with congenital anomalies. These infants were part of the NRN VLBW registry.1 (link)–6 (link)
Research personnel collected maternal pregnancy/delivery data soon after birth and infant data from birth to death, discharge/transfer, or 120 days of age (“status”). For infants with prolonged hospitalizations, limited information was collected up to 1 year. Definitions for maternal and infant characteristics were provided in a manual of operations. GA was determined as the best obstetric estimate by using ultrasonography and/or the date of the last menstrual period. Intrauterine growth restriction, defined as BW of <10th percentile for gender and GA, was determined by using growth charts published by Alexander et al.9 (link) Morbidities were defined in earlier publications,1 (link)–6 (link),10 (link),11 (link) including respiratory distress syndrome, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), early-onset and late-onset sepsis, necrotizing enterocolitis, patent ductus arteriosus, and retinopathy of prematurity (ROP). Respiratory distress syndrome was defined on the basis of clinical features and oxygen or respiratory support for ≥6 of the first 24 hours.
Three definitions of BPD were used, namely, traditional BPD (supplemental oxygen use at postmenstrual age [PMA] of 36 weeks); BPD determined by using the National Institutes of Health Workshop severity-based diagnostic criteria,12 (link) and BPD determined according to physiologic definition.13 (link) Surviving infants who were discharged or transferred before PMA of 36 weeks were classified on the basis of their status at 36 weeks, if status information was available, or oxygen use at discharge/transfer, if status information was not available. Unless noted otherwise, BPD refers to the traditional definition.
Revisions to data collection in 2006 included questions about maternal chorioamnionitis, placental pathologic conditions, nitric oxide use, and ibuprofen use and expanded data collection on birth resuscitation and neurologic, pulmonary, and ophthalmologic outcomes. In addition to ophthalmologic examination results and interventions, the following outcomes, defined in the manual of operations, were recorded: favorable in both eyes, severe ROP in either eye, or undetermined in either eye without severe ROP in either eye. Complete definitions are included in a footnote to Table 6. The registry was approved by the institutional review boards at each center.

Stoll B.J., Hansen N.I., Bell E.F., Shankaran S., Laptook A.R., Walsh M.C., Hale E.C., Newman N.S., Schibler K., Carlo W.A., Kennedy K.A., Poindexter B.B., Finer N.N., Ehrenkranz R.A., Duara S., Sánchez P.J., O’Shea T.M., Goldberg R.N., Van Meurs K.P., Faix R.G., Phelps D.L., Frantz ID I.I.I., Watterberg K.L., Saha S., Das A, & Higgins R.D. (2010). Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network. Pediatrics, 126(3), 443-456.

Publication 2010

Bronchopulmonary Dysplasia Childbirth Chorioamnionitis Congenital Abnormality Diagnosis Ethics Committees, Research Fetal Growth Retardation Genital Infantilism Hemorrhage Hospitalization Ibuprofen Infant Leukomalacia, Periventricular Lung Menstruation Mothers Necrotizing Enterocolitis Obstetric Delivery Oxide, Nitric Oxygen Patent Ductus Arteriosus Pathologic Processes Patient Discharge physiology Placenta Pregnancy Respiratory Distress Syndrome Respiratory Rate Resuscitation Retinopathy of Prematurity Septicemia Systems, Nervous Ultrasonography

Echocardiographic Evaluation of Preterm Infants

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015

Atrial Septal Defects Birth Birth Weight Bronchopulmonary Dysplasia Childbirth Congenital Abnormality Congenital Heart Defects Echocardiography Fetal Growth Retardation Gestational Age Heart Heart Ventricle Infant Infant, Newborn Left Ventricular Systolic Dysfunction Lung Mechanical Ventilation Menstruation Oxygen Patent Ductus Arteriosus Patients physiology Pregnancy Premature Birth Preterm Infant Pulmonary Artery Pulmonary Hypertension Respiration Disorders Respiratory Failure Respiratory Rate Right Ventricular Hypertrophy Syndrome Tricuspid Valve Insufficiency

Assessing Shared Decision-Making Concordance

Our main study of interest can be found in [30 (link)]. Data was collected from two previous studies, the Chest Pain Choice trial (Study 1) and the Osteroporosis Choice Randomized trial (Studies 2 and 3) [37 (link), 38 (link)]. Both trials randomly assigned patients to either receive an intervention of use of a Personal Decision Aid (PDA), or receive usual care [37 (link), 38 (link)]. The Osteoporosis Choice Randomized trial contains a subgroup of participants who used the World Health Organization’s Fracture Risk Assessment Tool (FRAX®;) [38 (link)]. For the purposes of our analysis, we consider patients who used FRAX®; as a separate study group (Study 3). The Chest Pain Choice trial recruited participants from St. Mary’s Hospital Mayo Clinic in Rochester, MN while the Osteoporosis Choice Randomized trial recruited from 10 general care and primary care practices in the Rochester, MN area [37 (link), 38 (link)].
Audio-visual recordings of the patient-clinician encounters took place and two-raters independently assessed the recording of each patient-physician encounter across these three clinical studies of decision-aids using the Observer OPTION⁵ SDM tool. A total of 311 clinical encounters were included in the study Table 1 summarizes these encounters across the three studies of interest. The overall Observer OPTION⁵ score was calculated for each encounter and rater [30 (link)]. The goal of the following analysis is to determine the concordance of the two raters despite the heterogeneity of the study groups and inherent heteroscedasticity.
Table 1

Encounters from the three randomized studies which compared the impact of PDAs to standard care

Study	PDA (n)	Usual care (n)	Total
1	101	100	201
2	37	35	72
3	13	25	38
Total	151	160	311

In this particular case, the recorded encounters from all three studies were re-rated by the same two raters. Hence, we assume that the differences across the studies are due to the differences in populations and imposed interventions across each study. In many cases, there would also be heterogeneity across raters of studies, leading to even greater between-study heterogeneity than is observed in this case.

Bobak C.A., Barr P.J, & O’Malley A.J. (2018). Estimation of an inter-rater intra-class correlation coefficient that overcomes common assumption violations in the assessment of health measurement scales. BMC Medical Research Methodology, 18, 93.

Publication 2018

Chest Pain Fracture, Bone Genetic Heterogeneity Health Risk Assessment Osteoporosis Patent Ductus Arteriosus Patients Population Group Primary Health Care

Comparing Outcomes of Moderately Preterm Infants

The NRN is a network of neonatal intensive care units (NICUs) at 18 academic centers in the United States and a data coordinating center, which was formed to conduct research to improve the care of high-risk infants. All infants between 29^0/7 to 33^6/7 weeks’ gestational age born January 2012 through November 2013 and admitted within the first 72 hours of life were included in the Moderately Preterm Registry. The comparison group was comprised of infants enrolled in the NRN Registry of inborn infants of gestational age 22^0/7 to 27^6/7 weeks (extremely preterm, EPT) or birth weight 401 to 1000 grams who were born during the same months. Infants who were born alive, but died in the delivery room were also included. Trained research nurses using pre-specified definitions abstracted maternal demographic, pregnancy, delivery and infant data from birth to discharge, transfer, death, or 40 weeks’ postmenstrual age (PMA), whichever occurred first. Detailed information on the EPT cohort by week of gestational age was published recently in JAMA (9 (link)). The Institutional Review Board at each center approved the registries.
Neonatal information included birth weight (BW), gestational age (GA), gender, race/ethnicity, mode of delivery, delivery room interventions, final status, and cause of death. Gestational age was determined as the best obstetric estimate by using ultrasonography and/or the date of the last menstrual period. Neonatal morbidities were recorded for infants surviving >12 hours, and included respiratory distress syndrome (RDS), patent ductus arteriosus (PDA), modified Bell’s Stage ≥IIA necrotizing enterocolitis (NEC) (10 (link)), any intracranial hemorrhage according to the criteria of Papile (11 (link)), severe intracranial hemorrhage (Grade III or IV), periventricular leukomalacia, retinopathy of prematurity (ROP) (12 (link)), bronchopulmonary dysplasia (BPD) defined as supplemental oxygen at 36 weeks’ postmenstrual age (PMA), and early- and late-onset sepsis defined by positive blood cultures before or after 72 hours of age. Cranial sonograms and ROP exams were performed based on usual center practice. Outcomes collected at 36 weeks’ PMA included the reason for continued hospitalization (continued respiratory support; persistent apnea and/or bradycardia – defined by local center practice; inadequate oral feedings defined by continued gavage feedings; other). Data collection continued until discharge or 40 weeks PMA, whichever occurred first. Only 16% of the cohort remained hospitalized at 40 weeks PMA.
The NRN has maintained a registry of the characteristics and outcomes of extremely preterm infants for over 20 years (9 (link)). We utilized this long standing registry to compare a cohort of MPT with a cohort of inborn EPT born during the same months. We further analyzed outcomes of MPT across the gestational age continuum. Statistical significance in this observational study was tested using the χ²test for categorical variables and the Kruskall-Wallis Test for continuous variables. Comparisons were made by gestational age and contrasted with the frequency seen in EPT born during the same time period.

WALSH M.C., BELL E.F., KANDEFER S., SAHA S., CARLO W.A., D’ANGIO C.T., LAPTOOK A.R., SANCHEZ P.J., STOLL B.J., SHANKARAN S., VAN MEURS K.P., COOK N., HIGGINS R.D., DAS A., NEWMAN N.S., SCHIBLER K., SCHMIDT B., COTTEN C.M., POINDEXTER B.B., WATTERBERG K.L, & TRUOG W.E. (2017). Neonatal Outcomes of Moderately Preterm Infants Compared to Extremely Preterm Infants. Pediatric research, 82(2), 297-304.

Publication 2017

Apnea Birth Weight Blood Culture Bronchopulmonary Dysplasia Childbirth Echoencephalography Enterocolitis Ethics Committees, Research Ethnicity Genital Infantilism Gestational Age Hospitalization Infant Infant, Extremely Premature Infant, Newborn Intracranial Hemorrhage Leukomalacia, Periventricular Menstruation Mothers Nurses Obstetric Delivery Oxygen Patent Ductus Arteriosus Patient Discharge Pregnancy Respiratory Distress Syndrome, Newborn Respiratory Rate Retinopathy of Prematurity Septicemia Tube Feeding Ultrasonography Vision

Systematic Review of Mobile EMA in Youth

Abstracts and full articles of the retrieved titles were screened for relevance. The article selection strategies, inclusion criteria, and exclusion criteria were determined in consensus meetings among authors. In order to be included in the systematic review, studies were required to (1) be an empirical study; (2) employ EMA strategies, including diary methods with more than one entry per day, ESM, and event sampling methods; (3) utilize mobile technologies for EMA data collection (cell phones, PDAs, smartphones, and so on); and (4) include children or adolescent (age ≤18 years) participants. Studies that involved adult participants (age >18 years), in addition to children and adolescents, were only included in the review if separate analytic or descriptive results were presented for the children or adolescents subgroups. Studies with any of the following 5 exclusion criteria were excluded: (1) did not utilize any electronic, wearable, or mobile technology; (2) utilized paper-based diaries to collect momentary data; (3) collected momentary or diary data once or less than once per day during the monitoring period; (4) utilized call-based (phone interview) data collection; and (5) data collection did not take place in free-living natural settings.

Wen C.K., Schneider S., Stone A.A, & Spruijt-Metz D. (2017). Compliance With Mobile Ecological Momentary Assessment Protocols in Children and Adolescents: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 19(4), e132.

Publication 2017

Adolescent Adult Child Patent Ductus Arteriosus

Most recents protocols related to «Patent Ductus Arteriosus»

Cardiac Dysfunction in Pediatric VSD with PAH

Our study cohort included eight children aged 6–10 years who were hospitalised in the Affiliated Hospital of Southwest Medical University, China on June 2022. Four of the children were diagnosed by echocardiography as VSD without PAH (control group, n = 4) and the other four were diagnosed by echocardiography and right cardiac catheterisation as moderate or severe PAH secondary to VSD (PAH group, n = 4). A diagnosis of PAH by right-heart catheterisation was defined as a mean pulmonary arterial pressure >25 mmHg at rest, a pulmonary capillary wedge pressure <15 mmHg and a pulmonary vascular resistance of >3 Wood units. We excluded patients receiving targeted therapy for PAH and those diagnosed with other intracardiac malformations, such as patent ductus arteriosus, large atrial septal defect, or other related conditions, like congenital lung disease, bronchial asthma and congenital pulmonary vascular malformation.
During the cardiac operation, atrial appendage specimens were collected from all patients before cardiopulmonary bypass and blood samples were collected via the jugular vein before performing the midline sternotomy. The plasma and right atrial appendage specimens were then aliquoted and stored at −80°C until RNA extraction.

Yang Q., Fan W., Lai B., Liao B, & Deng M. (2023). lncRNA-TCONS_00008552 expression in patients with pulmonary arterial hypertension due to congenital heart disease. PLOS ONE, 18(3), e0281061.

Publication 2023

Asthma Atrial Septal Defects Atrium, Right Auricular Appendage BLOOD Blood Vessel Cardiopulmonary Bypass Catheterizations, Cardiac Child Congenital Abnormality Congenital Disorders Echocardiography Jugular Vein Lung Lung Diseases Median Sternotomy Patent Ductus Arteriosus Patients Plasma Pulmonary Wedge Pressure Surgical Procedure, Cardiac Therapeutics Vascular Malformations

Retrospective Analysis of PAH Patients for Lung Transplant

We conducted a retrospective cohort study by analyzing the records of consecutive 43 patients with PAH referred for LT evaluation at the University of Tokyo Hospital from May 2014 to June 2020 (Fig. 1). The patients were in WHO functional class III or IV and had compromised hemodynamics despite optimal medical therapy. Among the 43 patients, three with contraindications to LT (hypertrophic cardiomyopathy, malignancy, or lack of family support) were excluded. Furthermore, three patients with right-to-left intracardiac shunt (one with patent ductus arteriosus and two with Eisenmenger’s syndrome due to atrial septal defect or ventricular septal defect) were also excluded from this study, as previously reported^{8 (link)}. Among the remaining of 37 patients, three patients with unavailable echocardiographic data were excluded, and 34 patients whose functional, laboratory, echocardiographic, and hemodynamic data was available were included in the analysis. The data for analysis was at the time of referral. The present study was performed according to the ethical guidelines of the University of Tokyo (approval by the Ethical Committee of the University of Tokyo: No. 2650) and in accordance with the Declaration of Helsinki. Due to nature of retrospective study, written informed consent was waived according to the approval by the Ethical Committee of the University of Tokyo.Figure 1

Flowchart of the study design, which included PAH patients referred for lung transplant evaluation. LT lung transplantation, PAH pulmonary arterial hypertension.

Ishii S., Minatsuki S., Hatano M., Saito A., Yagi H., Shimbo M., Soma K., Fujiwara T., Itoh H., Konoeda C., Sato M., Takeda N., Daimon M., Nakajima J, & Komuro I. (2023). The ratio of TAPSE to PASP predicts prognosis in lung transplant candidates with pulmonary arterial hypertension. Scientific Reports, 13, 3758.

Publication 2023

Atrial Septal Defects Echocardiography Eisenmenger Complex Hemodynamics Hypertrophic Cardiomyopathy Idiopathic Pulmonary Arterial Hypertension Lung Transplantation Malignant Neoplasms Patent Ductus Arteriosus Patients Therapeutics Ventricular Septal Defects

Comprehensive Neonatal Cardiac and Cerebral Monitoring

(1) Heart ultrasound to evaluate cardiac morphology, pulmonary pressures and patent ductus arteriosus (PDA), within the first 3 days of life and subsequently repeated, if needed; (2) Cerebral ultrasound within 48 hours of life and weekly thereafter, until discharge, if needed; (3) Routine measures to prevent BPD; routine fluid/nutritional policy; (4) Placement of umbilical central venous catheter and/or peripherally inserted central venous lines. Placement of arterial lines if needed, according to local policies and (5) Routine therapies according to local policies (ie, antibiotics, PDA closure drugs…).

Li Y., Zhu X, & Shi Y. (2023). Non-invasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in extremely preterm infants with respiratory distress syndrome: study protocol for a multicentre randomised controlled, superiority trial. BMJ Open, 13(3), e068450.

Publication 2023

Antibiotics, Antitubercular Arterial Lines Echocardiography Heart Lung Patent Ductus Arteriosus Patient Discharge Pharmaceutical Preparations Ultrasonics Umbilicus Veins Venous Catheter, Central

Predictors of Non-Invasive Ventilation Failure in Preterm Infants

The primary outcome was the incidence of NIV failure, defined as the need for mechanical ventilation within the first 72 h of life. As secondary outcomes, we examined ventilatory outcomes and neonatal morbidities to identify the risk factors associated with NIV failure. The pregnancy and delivery characteristics recorded included antenatal corticosteroid use, mode of delivery, gestational age, sex, birth weight, and Apgar score. Furthermore, we collected data on the type of ventilatory support used, duration and timing of ventilation, ventilator and respiratory parameters, surfactant and/or caffeine administration, FiO₂ before surfactant administration, and moment of initiation of Kangaroo Mother Care. Clinical outcomes were also recorded, including hospital stay, duration of supplemental oxygen, need for home oxygen, neonatal morbidities/complications, including BPD (need for respiratory support and/or additional oxygen at 36 postmenstrual weeks), air leak syndrome, grade III-IV intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP) >2, patent ductus arteriosus (PDA) with surgical treatment, necrotizing enterocolitis (NEC) Bell stage ≥2, pulmonary hemorrhage, and death.
Data were collected using a case record form developed for this study. The inclusion visit was performed at 24 h of life, and the infants were followed up at 72 h and at hospital transfer, discharge, or death. Information corresponding to the first hour after birth was retrospectively recorded.

Boix H., Fernández C., Serrano Martín M.D., Arruza L., Concheiro A., Gimeno A., Sánchez A., Rite S., Jiménez F., Méndez P, & Agüera J.J. (2023). Failure of early non-invasive ventilation in preterm infants with respiratory distress syndrome in current care practice in Spanish level-III neonatal intensive care units – a prospective observational study. Frontiers in Pediatrics, 11, 1098971.

Publication 2023

Adrenal Cortex Hormones Apgar Score Birth Birth Weight Caffeine Gestational Age Hemorrhage Infant Infant, Newborn Kangaroo-Mother Care Method Leukomalacia, Periventricular Lung Mechanical Ventilation Necrotizing Enterocolitis Obstetric Delivery Operative Surgical Procedures Oxygen Patent Ductus Arteriosus Patient Discharge Pregnancy Respiratory Rate Retinopathy of Prematurity Surfactants Syndrome

Neonatal Morbidities and Neuroimaging Outcomes

Maternal and neonatal data were abstracted from electronic medical records and charts. Antenatal and perinatal data: maternal age, medical conditions, place of birth, corticosteroids administration, mode of delivery, GA at birth, birth weight, sex, delayed cord clamping, invasive ventilation at birth, cord pH, Apgar score at 1 and 5 min.
Prematurity-related clinical morbidities: patent ductus arteriosus (PDA) requiring treatment, sepsis, hypotension requiring inotropes, bronchopulmonary dysplasia (the need for supplemental oxygen at 36 weeks' postmenstrual age), periventricular leukomalacia (PVL).
Ventricular measurements and fNIRS data: 2D cUS GMH-IVH staging (right, left), 3D cUS ventricle volumes (left, right and total), postnatal course during each measurement and resting state fNIRS data. For infants with PHVD, before and after each CSF diversion procedure: head circumference, weight, hemoglobin, respiratory support, tap volume, the need for VP shunt and brain MRI for those infants who went on to have one.

Kebaya L.M., Stubbs K., Lo M., Al-Saoud S., Karat B., St Lawrence K., de Ribaupierre S, & Duerden E.G. (2023). Three-dimensional cranial ultrasound and functional near-infrared spectroscopy for bedside monitoring of intraventricular hemorrhage in preterm neonates. Scientific Reports, 13, 3730.

Publication 2023

Adrenal Cortex Hormones Apgar Score Birth Weight Brain Bronchopulmonary Dysplasia Cerebral Ventricles Childbirth Cone-Rod Dystrophy 2 Head Heart Ventricle Hemoglobin Infant Infant, Newborn Inotropism Leukomalacia, Periventricular Mothers Obstetric Delivery Oxygen Patent Ductus Arteriosus Premature Birth Respiratory Rate Septicemia

Top products related to «Patent Ductus Arteriosus»

Escherichia coli strain dh5α by Takara Bio

Sourced in Japan, China

Escherichia coli strain DH5α is a commonly used laboratory strain of the bacterium Escherichia coli. It is a non-pathogenic strain that is frequently used in molecular biology and biotechnology applications due to its high transformation efficiency and stable maintenance of plasmid DNA.

Rhod 2 am by Thermo Fisher Scientific

Sourced in United States, Germany, United Kingdom, Canada

Rhod-2 AM is a fluorescent calcium indicator. It is used for the detection and measurement of intracellular calcium levels in live cells.

Sas 9 by SAS Institute

Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia

SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.

Affiniti 50g by Philips

Sourced in United States

The Affiniti 50G is a diagnostic ultrasound system designed by Philips. It features advanced imaging capabilities and is intended for use in various clinical settings. The Affiniti 50G provides high-quality imaging to support healthcare professionals in making informed clinical decisions.

Sonos 5500 by Philips

Sourced in United States, Germany, Japan, Netherlands, Norway

The Sonos 5500 is a laboratory equipment designed for ultrasound imaging and analysis. It features a high-resolution display and advanced signal processing capabilities. The device is capable of generating and receiving ultrasound signals for a variety of applications in research and diagnostic settings.

R version 3 by R Project for Statistical Computing

Sourced in United States, Austria, Japan, Belgium, New Zealand, United Kingdom, Germany, Denmark, Australia, France

R version 3.6.1 is a statistical computing and graphics software package. It is an open-source implementation of the S programming language and environment. R version 3.6.1 provides a wide range of statistical and graphical techniques, including linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, and more.

Streptomycin sulphate by Merck Group

Sourced in United States, Spain, Germany, Italy, Australia

Streptomycin sulphate is a powdered chemical compound used in laboratory settings. It is a salt formed from the combination of streptomycin and sulfuric acid. The product serves as a key ingredient in various microbiology and biochemistry applications.

Stata version 15 by StataCorp

Sourced in United States, Denmark, Austria, United Kingdom, Japan

Stata version 15 is a data analysis and statistical software package. It provides a range of tools for data management, statistical analysis, and visualization. Stata version 15 supports a variety of data types and offers a comprehensive set of statistical procedures.

Peptone by Thermo Fisher Scientific

Sourced in United Kingdom, United States, Italy, Belgium, China, Spain, Germany

Peptone is a complex mixture of amino acids and peptides derived from the enzymatic hydrolysis of proteins. It is commonly used as a nutrient source in culture media for the growth of microorganisms in laboratory settings.

Macs dissociator by Miltenyi Biotec

Sourced in Germany, United States, Italy

The MACS Dissociator is a lab equipment product from Miltenyi Biotec. It is designed to efficiently dissociate a variety of sample types, including tissues and cells, into single-cell suspensions for downstream applications.

What are the different types or variations of Patent Ductus Arteriosus (PDA)?

PDA can occur in different forms and severities. The most common types include: 1. Hemodynamically significant PDA: This type involves a large, persistent opening between the aorta and pulmonary artery, leading to a significant shunting of blood and potential complications. 2. Hemodynamically insignificant PDA: This refers to a smaller, clinically less relevant PDA that may not require immediate treatment. 3. Preterm PDA: PDA is more common in preterm infants, as the ductus arteriosus may fail to close properly due to the infant's immature cardiovascular system. 4. Syndromic PDA: PDA can also be associated with certain genetic syndromes or congenital disorders, such as Down syndrome or Rubinstein-Taybi syndrome.

How can PubCompare.ai assist researchers in optimizing PDA studies?

PubCompare.ai's AI-powered platform can help researchers optimize their PDA studies in several ways: 1. Efficiecnt literature screening: The platform allows you to quickly sreen through a large volume of protocol literature, saving valuable time. 2. Identification of critical insights: PubCompare.ai's intelligent analysis can hightlight key differences in the effectiveness of various PDA treatment protocols and products, enabling you to identify the most promising approaches for your research. 3. Informed decision-making: By leveraging the platform's data-driven insights, you can make more informed decisions about the best protocols and products to use in your PDA studies, improving the chances of reproducibility and accuracy. 4. Streamlined research process: PubCompare.ai's AI-powered comparisons and recommendations help streamline your PDA research process, allowing you to focus on the most productive and impactful aspects of your work.

What are some common challenges or considerations when using different PDA treatment protocols?

Some key challenges and considerations when using various PDA treatment protocols include: 1. Timing of intervention: Determining the optimal timing for PDA treatment, especially in preterm infants, can be critical for achieving the best outcomes. 2. Medication dosage: Properly adjusting the dosage of medications used to close the PDA, such as ibuprofen or indomethacin, is important to avoid potential side effects. 3. Surgical vs. non-surgical approaches: Deciding between surgical ligation and non-surgical, medication-based treatments requires careful evaluation of the patient's condition and risk factors. 4. Complications and side effects: Monitoring for and managing potential complications, such as bleeding, kidney dysfunction, or necrotizing enterocolitis, is essential when implementing PDA treatment protocols.

More about "Patent Ductus Arteriosus"

Patent Ductus Arteriosus (PDA) is a common congenital heart defect where the ductus arteriosus, a blood vessel that connects the pulmonary artery to the aorta, fails to close after birth.
This can lead to an abnormal blood flow between the two major blood vessels, potentially causing complications.
PDA is also known as persistent ductus arteriosus or open ductus arteriosus.
PubCompare.ai's AI-powered platform helps researchers optimize PDA research by comparing the effectiveness of various treatment protocols and products from scientific literature, preprints, and patents.
Its intelligent analysis enables researchers to identify the most effective approaches for their PDA studies with ease.
Researchers can utilize PubCompare.ai to explore different treatment options, such as surgical ligation, transcatheter closure, or pharmacological interventions like Escherichia coli strain DH5α or Streptomycin sulphate.
The platform can also help compare the performance of medical devices like Rhod-2 AM, Affiniti 50G, or Sonos 5500 in PDA management.
Additionally, PubCompare.ai's analytical tools can assist researchers in interpreting data from studies using statistical software like SAS 9.4, Stata version 15, or R version 3.6.1.
This can help identify the most effective treatment protocols and products for managing PDA, ultimately improving patient outcomes.
By leveraging PubCompare.ai's AI-powered insights, researchers can streamline their PDA studies, optimize their research strategies, and make more informed decisions about the most effective approaches to treating this common congenital heart defect.
The platform's ability to integrate data from various sources, including scientific literature, preprints, and patents, makes it a valuable tool for advancing PDA research and improving patient care.